Immune reconstitution, vaccine responses, and rituximab use after ex-vivo CD34-selected myeloablative allogenic hematopoietic cell transplantation
Bone Marrow Transplantation · 2024
DOI: 10.1038/s41409-024-02232-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bone Marrow Transplantation, 2024. Verfasst von Giovanna Melica und 11 weiteren Autor:innen. Beteiligte Einrichtung: Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Hauptthemen laut MEDLINE: Rituximab, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, U.S. Department of Health & Human Services | NIH | NIH Clinical Center (Clinical Center).
Abstract (Originalsprache)
Myeloablative T cell depleted (CD34-selected) hematopoietic cell transplantation (HCT) is associated with less acute and chronic graft versus host disease (GVHD). We aimed to examine vaccine responses in relation to immune reconstitution and post HCT rituximab administration in this population. This single center retrospective study included 251 patients with hematological malignancies who received a first CD34-selected HCT between 2012 and 2015. Of 251 patients, 190 were alive 1 year after HCT. Among the entire population, 77 (30.7%) patients were vaccinated. After vaccine administration, 35/44 (80%), 30/75 (40%), 27/36 (75%), 33/65 (51%), 34/51 (51%), 22/28 (79%) and 20/34 (59%) of evaluable patients had protective antibody titers for haemophilus influenzae type B (Hib), Pneumococcus, Tetanus, Diphtheria, Pertussis, hepatitis A (HAV), and hepatitis B (HBV) respectively. Responders to the pneumococcal vaccine had a higher CD45RA T cell count than non responders, with 12/18 patients (66.7%) vs 11/32 (34.4%) p = 0.04. For pneumococcal vaccine, there was also a trend to higher total lymphocyte B cell count in responders vs non responders p = 0.06. Rituximab post HCT was given to 59/251 (23.5%) patients. No difference was found in immune reconstitution patterns for rituximab use between vaccine responders and not. Recipients of CD34-selected HCT may respond to vaccination, and T and B cell subsets could be useful to predict vaccine response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Infectious Diseases and Clinical Immunology, Henri Mondor Hospital, APHP, Paris, France.
- Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
- Department of Hematology, Saint Antoine Hospital, Paris, France ; INSERM UMRs 938, Paris, France, Université Pierre et Marie Curie, Paris, France.
- Department of Hematology, Hackensack University Medical Center, John Theurer Cancer Center, Hackensack, NJ, USA.
- Department of Medicine, Weill Cornell Medical College, New York, NY, USA.
ORCID-Profile: Christina Cho, Gunjan L Shah, Miguel-Angel Perales
Förderung
- NCI NIH HHS
- U.S. Department of Health & Human Services | NIH | NIH Clinical Center (Clinical Center)
Zitieren
APA
Melica, G., Preston, E., Palazzo, M., Seier, K., Malard, F., Cho, C., Devlin, S. M., Maloy, M., Borrill, T., Maslak, P., Shah, G. L., & Perales, M. A. (2024). Immune reconstitution, vaccine responses, and rituximab use after ex-vivo CD34-selected myeloablative allogenic hematopoietic cell transplantation. Bone Marrow Transplantation. https://doi.org/10.1038/s41409-024-02232-3
Vancouver
Melica G, Preston E, Palazzo M, Seier K, Malard F, Cho C, et al. Immune reconstitution, vaccine responses, and rituximab use after ex-vivo CD34-selected myeloablative allogenic hematopoietic cell transplantation. Bone Marrow Transplantation. 2024. doi:10.1038/s41409-024-02232-3
BibTeX
@article{Melica2024,
author = {Melica, Giovanna and Preston, Elaina and Palazzo, Meighan and Seier, Kenneth and Malard, Florent and Cho, Christina and Devlin, Sean M and Maloy, Molly and Borrill, Taylor and Maslak, Peter and Shah, Gunjan L and Perales, Miguel-Angel},
title = {Immune reconstitution, vaccine responses, and rituximab use after ex-vivo CD34-selected myeloablative allogenic hematopoietic cell transplantation},
journal = {Bone Marrow Transplantation},
year = {2024},
doi = {10.1038/s41409-024-02232-3}
}
EUVIMED